Peter Schirmacher
Heidelberg University(DE)University Hospital Heidelberg(DE)Center for Personalized Cancer Treatment(NL)German Center for Infection Research(DE)Hopp Children's Cancer Center Heidelberg(DE)Chirurgische Universitätsklinik Heidelberg(DE)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Liver Disease Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Cholangiocarcinoma and Gallbladder Cancer Studies, Head and Neck Cancer Studies
Most-Cited Works
- → EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma(2018)11,334 cited
- → The 2019 WHO classification of tumours of the digestive system(2019)3,937 cited
- → Senescence surveillance of pre-malignant hepatocytes limits liver cancer development(2011)1,540 cited
- → NASH limits anti-tumour surveillance in immunotherapy-treated HCC(2021)1,186 cited
- → Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2018)1,047 cited
- → Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial(2016)720 cited